文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

由R263K联合E157Q介导的整合酶链转移抑制剂耐药:一例接受比克替拉韦/替诺福韦艾拉酚胺/恩曲他滨治疗的HIV感染患者病例报告及文献回顾

Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the literature.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

本文报告一例经治HIV患者因药物相互作用换用比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺(BIC/FTC/TAF)后,在依从性不佳情况下出现病毒学失败,检测到整合酶基因E157Q联合R263K及逆转录酶基因M184V等突变,提示BIC/FTC/TAF治疗中可体内选择E157Q联合R263K导致高阶整合酶链转移抑制剂耐药,虽属罕见现象。

要点

  • BIC/FTC/TAF治疗中依从性不佳可体内选择E157Q联合R263K及M184V导致高阶INSTI耐药。
  • 换用第二代INSTI前应关注既往第一代INSTI病毒学失败史。
  • 该患者换用多替拉韦每12小时一次联合增效达芦那韦及直接观察治疗后病毒载量低于100拷贝/mL。

核心结论

  • E157Q联合R263K及M184V可在BIC/FTC/TAF治疗且依从性不佳的临床情形下于体内被选择,尽管这是非常罕见的现象。
  • 换用第二代INSTI时,应牢记患者既往第一代INSTI的病毒学失败史。

研究设计与样本

  • 临床病例报告及文献回顾。
  • 报告一例经治HIV患者因药物相互作用换用BIC/FTC/TAF后出现病毒学失败。

主要发现

  • 患者为重度经治HIV感染者,因诊断为播散性鸟分枝杆菌-胞内分枝杆菌病后因药物相互作用换用BIC/FTC/TAF。
  • 患者既往接受雷特格韦治疗且依从性不佳,完成雷特格韦治疗1年后未检测到整合酶基因突变。
  • 换用BIC/FTC/TAF数月后,再次记录到依从性不佳,检测到病毒学失败。
  • 检测到整合酶基因多态性替换E157Q和耐药突变R263K,以及逆转录酶基因M184V等其他突变。
  • 患者目前接受多替拉韦每12小时一次联合增效达芦那韦及直接观察治疗,20年来首次血浆病毒载量低于100拷贝/mL。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The in vivo selection of E157Q plus R263K has not been reported in patients treated with coformulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). To the best of our knowledge, we hereby report the first case of high-grade INSTI resistance associated with the presence of these aminoacidic substitutions in a treatment-experienced HIV patient treated with BIC/FTC/TAF. METHODS: Clinical case report and review of the literature. RESULTS: A heavily treatment-experienced patient was switched to BIC/FTC/TAF due to drug-drug interactions after being diagnosed with disseminated Mycobacterium avium-intracellulare disease. He had been treated before with raltegravir with poor adherence. No mutations in the integrase gene were detected 1 year after finishing treatment with raltegravir. Months after being switched to BIC/FTC/TAF, and again with poor adherence documented, virological failure (VF) was detected. The polymorphic substitution E157Q and the resistance mutation R263K in the integrase gene were detected, as well as M184V, among other mutations in the reverse transcriptase gene. The patient is currently being treated with dolutegravir q12h plus boosted darunavir along with directly observed treatment, and for the first time in 20 years, plasmatic viral load values are below 100 copies/mL. CONCLUSIONS: This case illustrates that the combination of E157Q and R263K plus M184V can be selected in vivo in a clinical scenario of poor adherence with BIC/FTC/TAF, although it is a very rare phenomenon. Previous VF with first-generation integrase strand transfer inhibitors (INSTIs) should be kept in mind when switching patients to second-generation INSTIs.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Buzon-Martin L, Navarro-San Francisco C, Fernandez-Regueras M, et al. Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the literature. J Antimicrob Chemother. 2024. PMID: 38558010. doi:10.1093/jac/dkae085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。